• Grey LinkedIn Icon
  • Grey Facebook Icon
  • Grey YouTube Icon

© 2019 Taliaz Health Ltd. All rights reserved.

The Team

The Taliaz team combines a mix of business strategy and business development expertise, with extensive technological background in big data analytics and machine learning algorithms, neuroscience, genomic and clinical experience; which sets the company with the necessary capacities to have an impact on our target markets.

Dr. Dekel Taliaz

​Entrepreneur, experienced business manager and experimental neuroscientist.

Dr. Taliaz brings strong business acumen and has led Taliaz through all stages of fundraising, R&D, business development and marketing; turning an idea into a commercially available service.

 

He holds a PhD in Neuroscience from the Weizmann Institute in Israel and brings vast expertise in manipulating gene expression to determine genetic factors which underlie psychiatric disorders.  He founded Taliaz upon discovering that while there has been tremendous advances in DNA sequencing and computer technologies, the huge value from the vast amounts of genetic and clinical information available today is not being leveraged in clinical practice.

 

Dr. Taliaz is also the co–founder and Vice President of the Tech division of Israel Brain Technologies, which unites over 30 brain technology companies. He has also previously served as a clinical consultant for Brainsway (TASE:BRIN), a leading global neuromodulation company.  Dr. Taliaz has published numerous, highly-cited papers in leading peer-reviewed medical journals and received several honors and awards during his studies.

CEO & Co-Founder

Oren Taliaz

Entrepreneur and seasoned financial manager, bringing strong expertise in business development, funding, accounting and people management. 

Mr. Taliaz is also the founder and head of aro-trade, a recognized and successful capital market company, specializing in foreign currency trading and derivatives. As CEO, he manages all aspects of the company’s strategy, finances, operations and business development.  aro-trade now works with the trading rooms of Israel’s leading banks and with brokers on behalf of large institutional investors.

 

Mr. Taliaz was formerly a foreign currency trader for the well-known capital market company, Expert Finance Ltd (www.xp-f.com). Prior to this, he was a trader for the ETF specialists, Tachlit Ltd and a personal security guard, in charge of the team responsible for the personal security of the Eisenberg family.

 

He holds a degree in Industrial Engineering and Management from the Holon Institute of Technology in Israel. He served in the special infantries unit, Sayeret Givati, of the Israeli Defense Force.

CFO & Co-Founder

Sagee Lupin

Experienced technology innovation leader with nearly 15 years of experience in online development.

Mr. Lupin is a technology enthusiast with broad professional experience in successfully implementing
and managing a range of technologies and tools. He worked as a CTO for over a decade for the
telehealth company, Second Opinion, where he managed the company’s technology infrastructure. In

this hands-on role, he developed secure, complex web and mobile platforms from concept to ongoing
management as well as worked with major clients and global medical teams to establish medical call
centers.

 

He has previously worked as the CTO for Rio Technologies, a travel website firm, a Web Developer for
Earam Plastic Ltd, an industrial raw materials provider and a Technical Consultant for the home flight
check-in service, Premium Checkin. He received a BA in Social Science from Haifa University, Israel and
completed a Web Master Course from Sivan College, Israel.

CTO

Amit Spinrad

Experienced neurobiologist with focus on data science, bioinformatics and
genomics

Mr. Spinrad is a science enthusiast with broad interest and experience in various healthcare disciplines and widely skilled at analyzing complex data sets using state–of-the-art statistical and bioinformatic techniques. 


During his studies in Weizmann Institute of Science, he participated in the writing and creation of several high impact papers in leading peer-reviewed journals such as Science, Nature Communications and Cell. As a student, he was the co-administrator & co-author of the breakthrough 2017 Cell paper revealing DAM - a unique cell type that is related to neurodegenerative diseases and specifically Alzheimer’s disease, with more than 400 citations up to April 2019.


Mr. Spinrad had previously worked as a life-sciences data analyst in Signals Analytics, a data analytics platform company, and currently volunteers as a regular content writer for "Little Big Science", the biggest association in Israel providing accessibility of scientific innovation to the general public. 

He received a BSc Honors from the Hebrew University in Cognitive Sciences and Life Sciences, and MSc from Weizmann Institute of Sciences in Life Sciences with specialization in Alzheimer's disease, neuroimmunology, bioinformatics and transcriptomics.

Lead Scientist

Please reload

Advisors & Board Members

Keren Haruvi

Head of M&A at Novartis International AG, advising the Board and senior management, executing mid-large M&A activities across the Group and member of the Finance Leadership team.

From 2004 to October 2017, Ms. Haruvi served in various positions at Teva Pharmaceutical Industries including as Senior VP, Global Business Development and Alliance Management and Senior VP, Head of M&A and Transactions Analytics, evaluating and leading global M&A, divestitures and joint venture deals across the globe from scouting to closing and execution.

Director of the board

Prof. Stephen Stahl

M.D, PhD, Psychiatrist. An internationally recognized authority in psychiatry.

Dr. Stephen M. Stahl is an internationally recognized clinician, researcher, and teacher in psychiatry with subspecialty expertise in psychopharmacology and the current Adjunct Professor of Psychiatry at the University of California, San Diego.

 

Dr. Stahl has conducted numerous research projects awarded by the National Institute of Mental Health, the Veterans Administration, and the pharmaceutical industry. He is the author of over 500 scientific papers, edited 12 textbooks and personally written 35 textbooks including the two best-selling textbooks in the field of psychiatry and psychopharmacology over the past twenty years. He has contributed significantly to the field of psychopharmacology through his research in the 70s, 80s and 90s, especially in the area of serotonin, schizophrenia and depression.

 

Dr. Stahl has held faculty positions at Stanford University, the University of California at Los Angeles, the Institute of Psychiatry London and the Institute of Neurology London. Dr. Stahl was also Executive Director of Clinical Neurosciences at the Merck Neuroscience Research Center in the UK for several years.

 

Dr. Stahl received his undergraduate and medical degrees from Northwestern University in Chicago, as a member of the honors program in Medical Education and his Ph.D. degree in pharmacology and physiology from the University of Chicago. Dr. Stahl has trained in three specialties: internal medicine at the University of Chicago; neurology at the University of California in San Francisco; and psychiatry at Stanford University. He is board certified in psychiatry.

Scientific Advisory Board

Prof. Bernard Lerer

MD, Professor of Psychiatry and Director of the Biological Psychiatry Laboratory at Hadassah-Hebrew University Medical Center, Israel.

Prof. Lerer was chosen to lead Hadassah BrainLabs, National Knowledge Center for Research on Brain Disorders established at Hadassah Medical Center by the Israel Ministry of Science. His main research interests are the molecular genetic basis of major psychiatric disorders, particularly schizophrenia, depression, psychiatric genetics and pharmacogenetics and the neurochemical mechanisms of action of antidepressants, mood stabilizers and brain stimulation. He has a strong interest in internet based assessment and e-medicine development.

 

Prof. Lerer has extensive international research collaborations and has been Visiting Professor at the Universities of Cape Town, Copenhagen, Hiroshima and Miami. He has received research support from the National Institutes of Health, the European Union, the Israel Science Foundation and the Israel Ministries of Health, Science and Economics.

 

Prof. Lerer has published over 340 papers in peer-reviewed journals as well as book chapters and 4 books.

Scientific Advisory Board

Dr. Ran Barzilay

MD, PhD, Psychiatrist and Neuroscientist.  Brings multidisciplinary experience and unique insight as a practicing physician, psychiatrist and researcher.

Dr. Barzilay is a Child and Adolescent Psychiatry specialist. He is currently the Research Associate at the Lifespan Brain Institute of the Children’s Hospital of Philadelphia and UPenn Medicine, and psychiatry consultant for Preschool Day Care of children with Autistic Spectrum Disorders (ASD).  He was previously the resident psychiatrist at Geha Mental Health Center and a fellow researcher in the Felsenstein Medical Research Center Neuroscience Laboratory at Tel Aviv University.  He brings strong expertise in basic and translational neuroscience research in the fields of developmental psychopathology and stress related disorders.  

 

Dr. Barzilay received his medical degree, PhD and BSc at Sackler Faculty of Medicine in Tel-Aviv University, Israel.  He has also published numerous, highly-cited papers in leading peer-reviewed medical journals, written a book chapter, presented many abstracts at international conferences and has received several honors and awards during his studies.

Scientific Advisory Board

Please reload